

## Public Offering

# 60 Months EUR Worst of Memory Phoenix Autocall Certificates Linked to AstraZeneca PLC, Novartis AG, Roche Holding AG and Teva Pharmaceutical Industries Ltd

## Term Sheet

All material herein is for discussion purposes only and is only a summary. Reference should be made to the Programme, which contains the only legally binding terms of the Certificates and other information related to the issue. Investors should read the section "**Significant Risks**" below as well as the section "**Risk Factors**" of the Programme. **Investors are subject to the credit risk of the Issuer.** Until the Issue Date, the terms of this Termsheet are indicative and may be adjusted anytime. The Issuer is not obliged to issue the Product.

## PRODUCT DESCRIPTION

Product Description	This Product offers the investor a pre-defined conditional Coupon Amount with memory effect on the relevant Coupon Payment Date(s). In addition, the Certificates can also be redeemed early if the relevant conditions are met on any of the pre-defined Early Redemption Observation Dates. If no Early Redemption has occurred, the Redemption at maturity will depend on the performance of the Underlying with the Worst Performance. If the Final Fixing Level of the Underlying with the Worst Performance is at or above the Strike Level, the investor will receive a Cash Settlement equal to the Nominal Amount. Otherwise, the investor will receive a Cash Settlement calculated as the Nominal Amount multiplied by the Performance of the Underlying with the Worst Performance, as described under "Redemption".
Market expectation of the Investor	The investor expects a moderate rather than large rise in the Underlying(s). The investor expects that the Underlying with Worst Performance will close higher than the Strike Level on the Final Fixing Date of the Product.
EUSIPA / SSPA Code	1255 – Express without Barrier

## PRODUCT DETAILS

ISIN	IT0006765553
CFI Code	DEEVRB
Issue Price	EUR 1,000.00
Issue Size	10,000 Certificates
Nominal Amount	EUR 1,000
Settlement Currency	EUR
Minimum Investment	1 Certificate

## DATES

Initial Fixing Date	19 September 2024
Issue Date	23 September 2024
Final Fixing Date	19 September 2029
Redemption Date	28 September 2029

## UNDERLYING

i	Underlying	Related Exchange	Reference Currency	Bloomberg Ticker	Initial Fixing Level (100%)*	Strike Level (60.00%)*
1	AstraZeneca PLC	London Stock Exchange	GBP	AZN LN Equity	GBP 11,898.00	GBP 7,138.80
2	Novartis AG	SIX Swiss Exchange	CHF	NOVN SE Equity	CHF 98.44	CHF 59.064
3	Roche Holding AG	SIX Swiss Exchange	CHF	ROG SW Equity	CHF 267.50	CHF 160.50

4	Teva Pharmaceutical Industries Ltd	New York Stock Exchange	USD	TEVA UN Equity	USD 17.76	USD 10.656
---	------------------------------------	-------------------------	-----	----------------	-----------	------------

\* as determined on or about the Initial Fixing Date (levels are expressed in percentage of the Initial Fixing Level).

## GENERAL INFORMATION

Issuer	Marex Financial, 155 Bishopsgate, London, EC2M 3TQ, United Kingdom.
Issuer Rating	BBB (S&P Global).
Supervision of the Issuer	The Issuer is authorised and regulated in the United Kingdom by the Financial Conduct Authority ("FCA").
Calculation Agent	Marex Financial.
Principal Programme Agent	Not Applicable.
Names and addresses of additional Paying Agent(s) (if any):	BNP Paribas Securities Services, Milan Branch, Piazza Lina Bo Bardi 3, 20124 Milan.

## COUPON

Coupon Amount Provided that no Early Redemption has occurred on any one of the previous Early Redemption Observation Dates (N), the investor will receive on each Coupon Payment Date (n) an amount per Certificate in the Settlement Currency according to the following formula:

1. If the official closing price of each Underlying (i) on the relevant Coupon Determination Date (n) is equal to or higher than the corresponding Coupon Barrier:

**Nominal Amount x Sum of Coupon Rates – Previously Paid Coupons**

2. Otherwise, if the official closing price of any Underlying (i) on the relevant Coupon Determination Date (n) is lower than the corresponding Coupon Barrier then there will be no Coupon Amount payable.

Where,

Sum of Coupon Rates means the sum of all Coupon Rates(j) for the preceding and current Coupon Payment Dates (n).

Previously Paid Coupons means the sum of all Coupon Amounts due on any Coupon Payment Date (n) preceding such Coupon Payment Date (n) (provided that if no previous Coupon Amount have been paid prior to such Coupon Payment Date (n), then the sum of Previously Paid Coupon shall be zero).

Coupon Payment Dates

n	Coupon Barrier*	Coupon Rate <sub>j</sub>	Coupon Determination Date	Coupon Payment Date
1	60.00%	2.595%	19 December 2024	02 January 2025
2	60.00%	2.595%	19 March 2025	28 March 2025
3	60.00%	2.595%	20 June 2025	01 July 2025
4	60.00%	2.595%	19 September 2025	30 September 2025
5	60.00%	2.595%	19 December 2025	02 January 2026
6	60.00%	2.595%	19 March 2026	30 March 2026
7	60.00%	2.595%	22 June 2026	01 July 2026
8	60.00%	2.595%	21 September 2026	30 September 2026
9	60.00%	2.595%	21 December 2026	31 December 2026
10	60.00%	2.595%	19 March 2027	01 April 2027
11	60.00%	2.595%	21 June 2027	30 June 2027
12	60.00%	2.595%	20 September 2027	29 September 2027
13	60.00%	2.595%	20 December 2027	30 December 2027
14	60.00%	2.595%	20 March 2028	29 March 2028
15	60.00%	2.595%	20 June 2028	29 June 2028
16	60.00%	2.595%	19 September 2028	28 September 2028
17	60.00%	2.595%	19 December 2028	02 January 2029
18	60.00%	2.595%	19 March 2029	28 March 2029
19	60.00%	2.595%	20 June 2029	29 June 2029
20	60.00%	2.595%	19 September 2029	28 September 2029

\* levels are expressed as a percentage of the Initial Fixing Level.

The Coupon Determination Dates (n) are subject to Market Disruption Event provisions and the Coupon Payment Dates (n) are subject to the Business Day Convention.

## EARLY REDEMPTION

**Automatic Early Redemption Event** An Automatic Early Redemption Event occurs if the official closing price of each Underlying (i) is higher than the relevant Autocall Level (N) on any Early Redemption Observation Date (N) (including the Early Redemption Observation Date (N) which falls on the Final Fixing Date).

**Early Redemption Amount and Dates** If an Automatic Early Redemption Event occurs on any Early Redemption Observation Date (N), the Certificates will be automatically redeemed at the relevant Early Redemption Amount on the corresponding Early Redemption Date, as specified in the below table.

N	Autocall Level*	Early Redemption Amount**	Early Redemption Observation Date	Early Redemption Date
4	100.00%	100.00%	19 September 2025	30 September 2025
5	97.70%	100.00%	19 December 2025	02 January 2026
6	95.40%	100.00%	19 March 2026	30 March 2026
7	93.10%	100.00%	22 June 2026	01 July 2026
8	90.80%	100.00%	21 September 2026	30 September 2026
9	88.50%	100.00%	21 December 2026	31 December 2026
10	86.20%	100.00%	19 March 2027	01 April 2027
11	83.90%	100.00%	21 June 2027	30 June 2027
12	81.60%	100.00%	20 September 2027	29 September 2027
13	79.30%	100.00%	20 December 2027	30 December 2027
14	77.00%	100.00%	20 March 2028	29 March 2028
15	74.70%	100.00%	20 June 2028	29 June 2028
16	72.40%	100.00%	19 September 2028	28 September 2028
17	70.10%	100.00%	19 December 2028	02 January 2029
18	67.801%	100.00%	19 March 2029	28 March 2029
19	65.50%	100.00%	20 June 2029	29 June 2029
20	63.20%	100.00%	19 September 2029	28 September 2029

\* levels are expressed as a percentage of the Initial Fixing Level.

\*\* amounts are expressed as a percentage of the Nominal Amount.

The Early Redemption Observation Date(s) (N) are subject to Market Disruption Event provisions and the Early Redemption Dates (N) are subject to the Business Day Convention.

## REDEMPTION

**Formula** Provided that no Early Redemption Event has occurred on any one of the pre-defined Early Redemption Observation Dates (N) (including the Early Redemption Observation Date (N) which falls on the Final Fixing Date), the investor is entitled to receive from the Issuer on the Redemption Date an amount per Certificate in the Settlement Currency as determined by the Calculation Agent as follows:

- 1) If the Final Fixing Level of the Underlying with the Worst Performance is at or above its respective Strike Level, the investor will receive a Cash Settlement equal to:

**Nominal Amount**

- 2) If the Final Fixing Level of the Underlying with the Worst Performance is below its respective Strike Level, the investor will receive a Cash Settlement equal to:

**Nominal Amount × Worst Performance**

**Initial Fixing Level** Official closing price of Underlying(i) on the Initial Fixing Date on the Related Exchange as determined by the Calculation Agent.

**Relevant Fixing Level** For each relevant date, the official closing price of Underlying(i) on that date on the Related Exchange as determined by the Calculation Agent.

**Final Fixing Level** The Relevant Fixing Level of Underlying(i) on the Final Fixing Date.

Performance	For each Underlying(i) on any relevant date, the Performance is calculated as the Relevant Fixing Level of the Underlying(i) divided by the Strike Level.
Worst Performance	The Worst Performance corresponds to the Underlying(i) with the lowest Performance on the Final Fixing Date, as determined by the Calculation Agent.

## FURTHER INFORMATION

Unique Identifier	ae1e456b-a44b-43f2-ad16-544b67f0daab
Programme	Base Prospectus dated 29 September 2023, as supplemented from time to time, including the relevant Final Terms of the Product.
Notices	All notices concerning the Securities, including adjustments and corrections to the terms and conditions will be published on <a href="https://certificati.marex.com/">https://certificati.marex.com/</a> and notified to Monte Titoli.
Listing/Exchange	The Certificates may be listed on EuroTLX (a multilateral trading facility organised and managed by Borsa Italiana). No assurances are given that such listing will be obtained.
Business Days for payment purposes	TARGET.
Business Day Convention	Following.
Secondary Market	Under normal market conditions the Issuer will endeavour to quote secondary prices with a 1% bid and offer spread. The securities may only be sold to a third party with the prior consent of the Issuer and only in the form of a private placement. Thus, investors must contact the Issuer before they resell the Securities.
Quoting Type	Currency quotation. The securities are quoted dirty and any accrued interest is included in the secondary market price.
Settlement Type	Cash Settlement.
Selling Restrictions	The Products may not be offered or sold within the United States or to, or for the account or benefit of US persons (as defined in Regulation S). Detailed information on Selling Restrictions is published in the Programme which is available on <a href="https://certificati.marex.com/">https://certificati.marex.com/</a> .
Clearing	Monte Titoli.
Offer	Public Offering (see below under "Offering Information").
Offer State(s)	Italy, Luxembourg.
Form	Registered.
<b>Governing Law / Jurisdiction</b>	<b>English / England</b>
Section 871 (m)	The Issuer has determined that the Products will not be subject to withholding under Section 871 (m) of the U.S. Internal Revenue Code.

## TARGET MARKET

Positive Target Market	Target Market Category	Positive TM
	INVESTOR TYPE	Retail, Professional Client & Eligible Counterparty
	KNOWLEDGE AND EXPERIENCE	Informed & Advanced
	ABILITY TO BEAR LOSSES	No Capital Guarantee
	RISK TOLERANCE	High
	INVESTMENT OBJECTIVES	Income
	DISTRIBUTION STRATEGY	Self Directed, Investment Advice & Portfolio Management
	Time Horizon	Long Term
	May be terminated early?	YES

The Target Market Category is based on “Target Market Section” of the European MiFID Template - Version 4.0 definitions <https://www.bvi.de/en/services/samples-and-working-aids/european-mifid-template-emt/>

## TAXATION

Investors and prospective investors are advised to consult with their tax advisers with respect to the tax consequences of the purchase, ownership, disposition, lapse or exercise or redemption of a Product in light of their particular circumstances. The Issuer hereby expressly excludes any liability in respect of any possible tax implications.

### Information with regards to FATCA (Foreign Account Tax Compliance Act)

Any payment under this Product may be subject to withholding tax (such as, inter alia, withholding related to FATCA or 871(m) of the US Tax Code). Any payments due under this Product are net of such tax. If an amount in respect of Section 871(m) of the U.S. Tax Code were to be deducted or withheld from interest, principal or other payments on the Products, none of the Issuer, any Paying Agent or any other person would be required to pay additional amounts as a result of the deduction or withholding of such tax, i.e. the investor would receive a significant lower amount than he would have received without such deduction or withholding.

## OFFERING INFORMATION

Information for Italian, Luxembourg investors: This document is not a prospectus in terms of Regulation (EU) 2017/1129, and may not be interpreted as such. Reference should be made to the published Base Prospectus including any supplements thereto and the final terms relating to the Products, which contain the only legally binding terms of the Products. The final terms relating to the Products will be published in Italy on the first day of the public offering. The Base Prospectus, any supplements thereto and the Final Terms will be available for investors from the first day of the public offering in electronic form on the website [www.marexfp.com](http://www.marexfp.com). These documents are also obtainable free of charge at 155 Bishopsgate, London, EC2M 3TQ (United Kingdom), via telephone (+44 (0)207-650-4404\*) or via e-mail ([sales@marexfp.com](mailto:sales@marexfp.com)). The public offering of the Products in the Offer States is expected to commence on the date stated in the relevant final terms.

You understand that no action has been taken by Marex Financial to permit a public offering of the Products in any jurisdiction other than the ones stated above.

You agree that: (i) you will not offer, sell or deliver any of the Products described in this material in any jurisdiction, except in compliance with all applicable laws, and (ii) you will take, at your own expense, whatever action is required to permit your purchase and resale of the Securities. Where you receive a selling commission from Marex Financial you confirm that such payment complies with all applicable law in the territory into which you distribute the product, including where applicable that; (i) you have disclosed the nature and amount of the payment to the extent you are required to do so; (ii) you have confirmed that the receipt of any payment by you from Marex Financial does not conflict with your duty to act in the best interests of those to whom you owe such duties; and (iii) you have determined that the payment is designed to enhance the quality of the service to any investor seeking to invest in the investments set out in this material.

## PRODUCT DOCUMENTATION

Notices to investors in connection with this Product shall be validly given in accordance with the terms and conditions of the Programme.

During the whole term of this Product, the Product Documentation can be ordered free of charge from the Calculation Agent/the Issuer at 155 Bishopsgate, London, EC2M 3TQ (United Kingdom), via telephone (+44 (0)20 8050 3561\*) or via e-mail

(sales@marexfp.com). Please note that all calls made to numbers marked with an asterisk (\*) are recorded. By calling such number, your consent to the recording is deemed given.

## SIGNIFICANT RISKS

### Risk Factors Relating to the Product

The risk of loss related to this Product is similar to an investment in the Underlying with the Worst Performance.

Therefore, the investor could lose the total capital invested if the value of the Underlying with the Worst Performance falls to zero on the Final Fixing Date.

### Additional Risk Factors

Prospective investors should ensure that they fully understand the nature of this Product and the extent of their exposure to risks and they should consider the suitability of this Product as an investment in the light of their own circumstances and financial condition. Products involve a high degree of risk, including the potential risk of expiring worthless. Potential investors should be prepared in certain circumstances to sustain a total loss of the capital invested to purchase this Product. Prospective investors shall consider the following important risk factors and see the section "Risk Factors" of the Programme for details on all other risk factors to be considered.

This is a structured product involving derivative components. Investors should make sure that their advisors have verified that this Product is suitable for the portfolio of the investor taking into account the investor's financial situation, investment experience and investment objectives.

The terms and conditions of the Product may be subject to adjustments during the lifetime of the Product as set out in the Programme. Investors whose usual currency is not the currency in which the Product is redeemed should be aware of their possible currency risk. The value of the Product may not correlate with the value of the Underlying.

### Market Risks

The general market performance of securities is dependent, in particular, on the development of the capital markets which, for their part, are influenced by the general global economic situation as well as by the economic and political framework conditions in the respective countries (so-called market risk). Changes to market prices such as interest rates, commodity prices or corresponding volatilities may have a negative effect on the valuation of the Underlying(s) or the Product. There is also the risk of market disruptions (such as trading or stock market interruptions or discontinuation of trading) or other unforeseeable occurrences concerning the respective Underlyings and/ or their stock exchanges or markets taking place during the term or upon maturity of the Products. Such occurrences can have an effect on the time of redemption and/or on the value of the Products.

### No Dividend Payment

This Product does not confer any claim to receive rights and/ or payments of the Underlying, such as dividend payments, unless explicitly stated herein, and therefore, without prejudice to any coupon or dividend payments provided for in this Termsheet, does not yield any current income. This means that potential losses in value of the Product cannot be compensated by other income.

### Credit Risk of Issuer

Investors bear the credit risk of the Issuer of the Product. The value of the Products is dependent not only on the Underlyings, but also on the creditworthiness of the Issuer, which may change over the term of the Product.

The Products constitute unsubordinated and unsecured obligations of the Issuer and rank pari passu with each and all other current and future unsubordinated and unsecured obligations of the Issuer. The insolvency of the Issuer may lead to a partial or total loss of the invested capital.

### Secondary Market

The Issuer or any third party appointed by the Issuer, as applicable, intends, under normal market conditions, to provide bid and offer prices for the Products on a regular basis (if specified in the section "General Information"). However, the Issuer makes no firm commitment to provide liquidity by means of bid and offer prices for the Products, and assume no legal obligation to quote any such prices or with respect to the level or determination of such prices. In special market situations, where the Issuer is unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices may be temporarily expanded, in order to limit the economic risks of the Issuer. Investors must be prepared to hold the Securities until the Redemption Date.

### Illiquidity Risk

One or, if applicable, more of the Underlyings might be or become illiquid over the life time of the Product.

Illiquidity of an Underlying might lead to larger bid/ offer spreads of the Product and/or to an extended time period for buying and/ or selling the Underlying respective to acquire, unwind or dispose of the hedging transaction(s) or asset(s) or to realise, recover or rem it



the proceeds of such hedging transaction(s) or asset(s) which might implicate a postponed redemption or delivery and/ or a modified redemption amount, as reasonably determined by the Calculation Agent.

## ADDITIONAL INFORMATION / DISCLAIMERS

### Conflict of Interests

The Issuer and/or any third party appointed by them, as the case may be, may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market as well as be active on both sides of the market at the same time in any securities, currencies, financial instruments or other assets underlying the products to which this document relates. The Issuer's and/ or the appointed third party's trading and/ or hedging activities related to this transaction may have an impact on the price of the Underlying and may affect the likelihood that any relevant threshold (e.g. a Barrier Level/Price), if any, is reached.

### Remunerations to Third Parties

Depending on the circumstances the Issuer may sell this Product to financial institutions or intermediaries at a discount to the Issue Price or reimburse a certain amount to such financial institutions or intermediaries (reference is made to section "General Information" herein). For open-end products such fees will be split linearly over ten years.

In addition, for certain services rendered by distribution partners and to increase quality and services relating to the Products, the Issuer may from time to time pay trailer fees to such third parties.

Further information is available on request.

### Payment of a Coupon

If the Product stipulates the payment of a coupon, the investor is only entitled to receive the respective coupon payment, if he has purchased/not sold the Product at the latest on the business day preceding the respective Coupon Payment Date for the then prevailing price.

### No Offer

The Termsheet is primarily provided for information purposes and does not constitute a recommendation, an offer or a solicitation of an offer to buy financial products.

### No Representation

The Issuer and any third party appointed by them make no representation or warranty relating to any information herein which is derived from independent sources.

### No Advice

This Termsheet should not be construed as investment, financial, strategic, legal, regulatory, accounting or tax advice. It does not take into account the particular investment objectives, financial situation or needs of individual investors. Certain transactions, including those involving futures, options and high yield securities, give rise to substantial risk and are not suitable for all investors. Accordingly investors should consider whether the Products described herein are suitable for their particular circumstances and should consult their own accounting, tax, investment and legal advisors before investing. Marex Financial is not acting as an advisor or fiduciary. Marex Financial does not accept any responsibility to update any opinions or other information contained in this Termsheet.

### No Bank Deposits

The Products are not bank deposits insured or guaranteed by the UK Financial Services Compensation Scheme or any other governmental agency or deposit protection fund run by public, private or community banks.

## DISCLAIMER

This document has been prepared by Marex Financial Products, a division of Marex Financial, for information purposes only. It is not intended as an offer or solicitation of the purchase or sale of any securities, funds, structured products or any other structured investment products ("Structured Investment Products"). Purchasing Structured Investment Products involve derivatives and a higher degree of risk factors that may not be suitable for all investors. Such risks include risk of adverse or unanticipated market developments, issuer credit quality risk, risk of counterparty or issuer default, risk of lack of uniform standard pricing, risk of adverse events involving any underlying reference obligations, entity or other measure, risk of high volatility, and risk of illiquidity/ little to no secondary market. In certain transactions, investors may lose their entire investment, i.e., incur an unlimited loss.

This document may only be distributed in countries where its distribution is legally permitted and may not be distributed in the US or to US persons. This document may not be distributed by Marex Financial Products or any distributor publicly and is only suitable for Qualified Investors (within the meaning of Regulation (EU) 2017/1129) or equivalent investors.



This document was approved by Marex Financial. Marex Financial is incorporated under the laws of England and Wales (company no. 5613061, LEI no. 5493003EETVWYSIJ5A20 and VAT registration no. GB 872 8106 13) and is authorised and regulated by the Financial Conduct Authority (FCA registration number 442767). Marex Financial's registered address is at 155 Bishopsgate, London, EC2M 3TQ.